Comparative risk of new-onset diabetes following commencement of antipsychotics in New Zealand: a population-based clustered multiple baseline time series design

BMJ Open
Olivia CurriePaul Bridgford

Abstract

Newer antipsychotics are increasingly prescribed off-label for non-psychotic ailments both in primary and secondary care settings, despite the purported risk of weight gain and development of type 2 diabetes mellitus. This study aims to determine any relationship between the development of clinically significant new-onset type 2 diabetes mellitus and novel antipsychotic use in New Zealand using hypnotic drugs as control. A population-based clustered multiple baseline time series design. Routinely collected data from a complete national pharmaceutical database in New Zealand between 2005 and 2011. Patients aged 40-60 years in the year 2006 who were ever dispensed antipsychotics (exposure groups-first-generation antipsychotics, second-generation antipsychotics and antipsychotics with low, medium and high risk for weight gain) or hypnotics (control group) between 2006 and 2011. First ever metformin dispensed to patients in each study group between 2006 and 2011 as proxy for development of clinically significant type 2 diabetes mellitus, no longer amendable by lifestyle modifications. Patients dispensed a second-generation antipsychotic had 1.49 times increased risk (95% CI 1.10 to 2.03, p=0.011) of subsequently commencing metformi...Continue Reading

References

Aug 4, 2007·American Journal of Preventive Medicine·Nathan G HawkinsLawrence W Green
Jan 30, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·David N JuurlinkMuhammad M Mamdani
Jul 1, 2010·Public Health Nutrition·Asnawi AbdullahAnna Peeters
Sep 30, 2010·Pharmacotherapy·Scott G WilliamsDavid F Cruess
Oct 5, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Lars Vedel KessingPer Kragh Andersen
Jan 22, 2011·Pharmacoepidemiology and Drug Safety·G C AlexanderR S Stafford
Sep 22, 2011·Expert Opinion on Pharmacotherapy·Michael Rosenbluth, Mark Sinyor
Sep 24, 2011·American Journal of Public Health·Dale A RhodaErinn M Hade
Sep 29, 2011·JAMA : the Journal of the American Medical Association·Alicia Ruelaz MaherPaul G Shekelle
Oct 17, 2012·Australian Journal of Primary Health·Susanne H Stanley, Jonathan D E Laugharne
Apr 4, 2013·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Jocelyne MoisanJean-Pierre Grégoire
Mar 19, 2014·Journal of Internal Medicine·J Hallas, A Pottegård
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Nov 18, 2014·Expert Opinion on Drug Safety·Richard MusilMichael Hamerle
Feb 11, 2015·BMJ : British Medical Journal·K HemmingR J Lilford
Jun 11, 2015·BMJ : British Medical Journal·Evangelos KontopantelisDavid Reeves
Nov 26, 2016·European Journal of Clinical Pharmacology·Prasad S Nishtala, Te-Yuan Chyou

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA

Software Mentioned

R
geepack

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here